Redeye shares its view on Xspray’s study results with HyNap-Dasa. There is no denying that the study is a fail, as HyNap-Dasa did not show bioequivalence with Sprycel. However, the underlying factors affecting the results are hard to interpret and we recognise there are several possible scenarios going forward. With the information we have to date, we believe it is wise to assume that an additional trial will be needed. In our new Base case, we factor in that an additional trial will be required for an ANDA application, suggesting a delay in the timeline of about 6-9 months. This leaves us with a new Base case of SEK 165 (190). We do not see these data affecting the value of the rest of Xspray’s PKI pipeline.